Satellos Bioscience Common Stock EBIT

Satellos Bioscience Common Stock (MSLE) currently reports a EBIT of $-35M as of June 2026. That compares with $-20M in the prior-year period — down 78.2% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Satellos Bioscience Common Stock's EBIT history and peer comparisons.

Satellos Bioscience Common Stock's EBIT decreased from $-20M to $-35M — a 78.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Satellos Bioscience Common Stock's EBIT of $-35M is lower than the its sector sector average of $-6.4M. That is roughly 452.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Satellos Bioscience Common Stock reported $-35M in EBIT as of June 2026. That compares with $-20M in the prior-year period — down 78.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-35M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Satellos Bioscience Common Stock, and consider following MSLE for alerts when major investors trade the stock.